Yahoo! FinanceHome - Yahoo! - Help

Market Guide

[ Stock Screener | Company & Fund Index | Financial Glossary ]

Profile - OSI Pharmaceuticals, Inc. (NasdaqNM:OSIP)
As of 31-Aug-2001
Enter symbol:
symbol lookup

 
More Info: Quote | Chart | News | Profile | Research | SEC | Msgs | Insider | Options | Financials | Reports
Recent Events
Aug 14Earnings Announcement
Location
58 S. Service Road, Suite 110
Melville, NY 11747
Phone: (631) 962-2000
Email: kgalante@osip.com
Employees (last reported count): 221
Financial Links
 ·Top Institutional Holders
 ·Top Mutual Fund Holders
 ·Analyst Upgrade/Downgrade History
 ·Historical Quote Data
 ·Free Annual Report
 ·Raw SEC Filings at sec.gov
Competitors:
 ·Sector: Healthcare
 ·Industry: Biotechnology & Drugs
Company Websites
 ·Home Page
 ·Investor Relations
 ·Employment
 ·Yahoo! Category

 ·Search Yahoo! for related links...

Ownership
·Insider and 5%+ Owners: 29%
·Over the last 6 months:
 · 16 insider sells; 146.0K shares
  (1.4% of insider shares)
·Institutional: 75% (105% of float)
(247 institutions)
·Net Inst. Buying: 896.0K shares (+3.31%)
(prior quarter to latest quarter)
More From Market Guide
 ·Highlights
 ·Performance
 ·Ratio Comparisons
Business Summary
OSI Pharmaceuticals, Inc. is a biopharmaceutical company focused on the discovery and development of gene-targeted, small molecule drugs, in the areas of cancer, respiratory diseases, diabetes and cosmeceuticals. Independently, and with its corporate partners, the Company has built a pipeline of discovery programs and drug candidates for 46 individual gene targets, addressing major, unmet clinical needs and significant commercial opportunities. The Company has two candidates in clinical trials and nine projects with candidates in late stage pre-clinical development. OSI-774, the Company's small molecule anti-cancer agent, is a potent, selective and orally active inhibitor of epidermal growth factor receptor (EGFR). The protein product of the EGFR gene is a receptor tyrosine kinase (RTK) that is over-expressed in approximately 30% of all major cancers. OSI-774 is an oral, once-a-day small molecule drug designed to specifically block the activity of the EGFR protein.
More from Market Guide: Expanded Business Description

Financial Summary
OSI Pharmaceuticals, Inc. utilizes a platform of proprietary technologies in order to discover and develop novel, small molecule compounds for the treatment of major human diseases. For the nine months ended 6/30/01, revenues decreased 12% to $19.6 million. Net loss before acct. change rose 43% to $6.4 million. Revenues reflect the conclusion of funded collaborations. Net loss also reflects the absence of a $3.7 million gain on the sale of the diagnostics business.
More from Market Guide: Significant Developments

Officers[Insider Trade Data]
FY2000 Compensation
PayExer

Colin Goddard, Ph.D., 41
Chairman, CEO
$533K$1.8M
Nicholas Bacopoulos, Ph.D., 51
Pres and Head of R&D
--  --  
Robert Van Nostrand, 43
CFO, Treasurer, VP, Sec.
199K1.7M
Arthur Bruskin, Ph.D., 45
Exec. VP, Pharmaceutical Operations
266K2.3M
Eric Collington, Ph.D., 55
VP - Chemistry
--  --  
Dollar amounts are as of 30-Sep-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.; "Exer" is the value of options excercised during the fiscal year.
More from Market Guide on Officers & Directors:
Expanded List, Bios, Compensation, Options
Statistics at a Glance -- NasdaqNM:OSIPAs of 31-Aug-2001
Price and Volume
52-Week Low
on 22-Mar-2001
$30.188
Recent Price$42.40 
52-Week High
on 6-Nov-2000
$86.375
Beta0.74 
Daily Volume (3-month avg)359.5K
Daily Volume (10-day avg)303.0K
Stock Performance
[one-year price graph]
big chart [1d | 5d | 3m | 6m | 1y | 2y | 5y | max]
52-Week Change-11.7%
52-Week Change
relative to S&P500
+18.5%
Share-Related Items
Market Capitalization$1.48B
Shares Outstanding34.9M
Float24.8M
Dividends & Splits
Annual Dividendnone 
Last Splitnone 
Per-Share Data
Book Value (mrq)$16.12 
Earnings (ttm)-$0.70 
Earnings (mrq)-$0.14 
Sales (ttm)$0.82 
Cash (mrq)$16.40 
Valuation Ratios
Price/Book (mrq)2.63 
Price/EarningsN/A 
Price/Sales (ttm)51.52 
Income Statements
Sales (ttm)$26.0M
EBITDA (ttm)-$38.6M
Income available to common (ttm)-$18.3M
Profitability
Profit Margin (ttm)-70.4%
Operating MarginN/A 
Fiscal Year
Fiscal Year EndsSep 30
Most recent quarter30-June-2001
Management Effectiveness
Return on Assets (ttm)-4.84%
Return on Equity (ttm)-5.09%
Financial Strength
Current Ratio (mrq)39.71 
Debt/Equity (mrq)0 
Total Cash (mrq)$571.6M
Short Interest
As of 8-Aug-2001
Shares Short873.0K
Percent of Float3.5%
Shares Short
(Prior Month)
962.0K
Short Ratio2.42 
Daily Volume361.0K
See Profile Help for a description of each item above;   K = thousands;   M = millions;   B = billions;   mrq = most-recent quarter;   ttm = trailing twelve months;   (as of 30-June-2001)

Market Guide offers more in-depth Company Research, Stock Screening, and Hottest Stocks and Industries on over 10,000 U.S. Equities.


Copyright © 2001 Yahoo! Inc. All Rights Reserved. Privacy Policy - Terms of Service
Company information Copyright Market Guide. Historical chart data and daily updates provided by Commodity Systems, Inc. (CSI). Event data provided by CCBN. Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Yahoo nor any of its data or content providers (such as Market Guide, CSI, etc.) shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon.